Trial · NCT01691781
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
NCT01691781, Not applicable, Completed, Brigham and Women's Hospital; results first posted 2017-08-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study. Trials, record NCT01691781. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01691781
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
- NCT number
- NCT01691781
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 41 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Hyperparathyroidism
- Interventions
- Lisinopril
- First posted
- 2012-09-25
- Last updated
- 2017-09-21
- Results first posted
- 2017-08-10
- Limitations and caveats
This a small physiology pilot study that is open-label and non-randomized. The intervention was an ACE inhibitor, an approved therapy. Results have physiologic implications, but treatment implications are not intended.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration | 1 week | PTH values 1 week following ACE inhibitor therapy |
| Secondary | Urinary Aldosterone Excretion Measurements Following 1 Week of ACE Inhibitor Therapy | 1 week | |
| Secondary | Serum Calcium Following 1 Week of ACE Inhibitor Administration | 1 week |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration | 1 week | pg/mL | MEAN | |
| SECONDARY | Urinary Aldosterone Excretion Measurements Following 1 Week of ACE Inhibitor Therapy | 1 week | mcg/24 hours | MEAN | |
| SECONDARY | Serum Calcium Following 1 Week of ACE Inhibitor Administration | 1 week | mg/dL | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration | Primary Hyperparathyroidism | 70.9 | Standard Deviation 19.6 | pg/mL | |
| Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration | Normal | 32.5 | Standard Deviation 16.7 | pg/mL | |
| Urinary Aldosterone Excretion Measurements Following 1 Week of ACE Inhibitor Therapy | Primary Hyperparathyroidism | 7.8 | Standard Deviation 8.9 | mcg/24 hours | |
| Urinary Aldosterone Excretion Measurements Following 1 Week of ACE Inhibitor Therapy | Normal | 6.1 | Standard Deviation 9.1 | mcg/24 hours | |
| Serum Calcium Following 1 Week of ACE Inhibitor Administration | Primary Hyperparathyroidism | 10.5 | Standard Deviation 0.4 | mg/dL | |
| Serum Calcium Following 1 Week of ACE Inhibitor Administration | Normal | 9.5 | Standard Deviation 0.3 | mg/dL |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Primary Hyperparathyroidism | 19 | |
| Overall Study | STARTED | Normal | 22 | |
| Overall Study | COMPLETED | Primary Hyperparathyroidism | 12 | |
| Overall Study | COMPLETED | Normal | 15 | |
| Overall Study | NOT COMPLETED | Primary Hyperparathyroidism | 7 | |
| Overall Study | NOT COMPLETED | Normal | 7 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Weakness | General disorders | Primary Hyperparathyroidism | 1 | 12 | 1 |
| other | Weakness | General disorders | Normal | 0 | 15 | 0 |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Primary Hyperparathyroidism | 1 | 12 | 1 |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Normal | 0 | 15 | 0 |
| other | diarrhea | Gastrointestinal disorders | Primary Hyperparathyroidism | 0 | 12 | 0 |
| other | diarrhea | Gastrointestinal disorders | Normal | 1 | 15 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Primary Hyperparathyroidism | 0 | 12 |
| Total, all-cause mortality | Normal | 0 | 15 |
| Total, other adverse events | Primary Hyperparathyroidism | 2 | 12 |
| Total, other adverse events | Normal | 1 | 15 |
| Total, serious adverse events | Primary Hyperparathyroidism | 0 | 12 |
| Total, serious adverse events | Normal | 0 | 15 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28808443 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Primary Hyperparathyroidism vs Normal: deaths from any cause | Trial comparisons |
| Primary Hyperparathyroidism vs Normal: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01691781
GET https://conductscience.org/api/trials/v1/NCT01691781/registered